Citadel Advisors’s Astria Therapeutics ATXS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-100
| Closed | -$534 | – | 12478 |
|
|
2025
Q1 | $534 | Sell |
100
-100
| -50% | -$700 | ﹤0.01% | 14249 |
|
|
2024
Q4 | $1.79K | Sell |
200
-3,100
| -94% | -$32.9K | ﹤0.01% | 14149 |
|
|
2024
Q3 | $36.3K | Sell |
3,300
-23,900
| -88% | -$266K | ﹤0.01% | 12252 |
|
|
2024
Q2 | $248K | Sell |
27,200
-35,000
| -56% | -$342K | ﹤0.01% | 9512 |
|
|
2024
Q1 | $875K | Buy |
62,200
+61,700
| +12,340% | +$768K | ﹤0.01% | 7198 |
|
|
2023
Q4 | $3.84K | Sell |
500
-600
| -55% | -$3.32K | ﹤0.01% | 13552 |
|
|
2023
Q3 | $8.21K | Sell |
1,100
-4,400
| -80% | -$37.5K | ﹤0.01% | 13211 |
|
|
2023
Q2 | $45.8K | Buy |
5,500
+3,900
| +244% | +$45K | ﹤0.01% | 11905 |
|
|
2023
Q1 | $21.3K | Sell |
1,600
-10,400
| -87% | -$141K | ﹤0.01% | 13025 |
|
|
2022
Q4 | $179K | Buy |
+12,000
| New | +$124K | ﹤0.01% | 10334 |
|
|
2021
Q2 | – | Sell |
-3,100
| Closed | -$54K | – | 13638 |
|
|
2021
Q1 | $54K | Buy |
3,100
+200
| +7% | +$3.61K | ﹤0.01% | 12869 |
|
|
2020
Q4 | $37K | Buy |
2,900
+583
| +25% | +$10.4K | ﹤0.01% | 10667 |
|
|
2020
Q3 | $86K | Buy |
+2,317
| New | +$91.8K | ﹤0.01% | 9356 |
|
Citadel Advisors's ATXS Position: Q1 2026 in Review
Citadel Advisors sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 113,555 shares — an estimated $1.49M sold.
Citadel Advisors first reported a position in ATXS in Q1 2017 and held it in 25 quarters. The position peaked at $12.9M in Q2 2024. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.
- Citadel Advisors reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
- Citadel Advisors sold 113,555 Astria Therapeutics shares in Q1 2026, an estimated $1.49M.
- Citadel Advisors first reported a position in Astria Therapeutics in Q1 2017 and held it in 25 quarters.
- Citadel Advisors's Astria Therapeutics position peaked at $12.9M in Q2 2024.
- 0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.